Zymeworks Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report0 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
+1.77%
vs ±20.7% implied · ×0.09
shaded = implied · ▲▼ = realized
| Manager | Value | % base | |
|---|---|---|---|
| EcoR1 Capital | $600.4M | 33.50% | 0.00% |
| Rubric | $183.0M | 10.21% | 0.00% |
| BlackRockindex-like | $111.1M | 6.20% | −6.65% |
| Perceptive | $109.3M | 6.10% | +19.17% |
| BVF | $95.4M | 5.32% | −2.28% |
| Manager | Value | % base | |
|---|---|---|---|
| EcoR1 Capital | $600.4M | 33.50% | 0.00% |
| Rubric | $183.0M | 10.21% | 0.00% |
| BlackRockindex-like | $111.1M | 6.20% | −6.65% |
| Perceptive | $109.3M | 6.10% | +19.17% |
| BVF | $95.4M | 5.32% | −2.28% |
Annual filing, covered
10-K parsed · Mar 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 2 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
No thesis.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, and breast cancer; and ZW49, a biparatopic anti- human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; and BeiGene, Ltd. It also has licensing and research collaboration with LEO Pharma A/S to discover and develop bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was founded in 2003 and is headquartered in Vancouver, Canada.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Zymeworks Inc.'s 6 closest co-movers, none share that code.
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; of Zymeworks Inc.'s 6 closest co-movers, none share that code.
Tall tick = annual report · Source: EDGAR
Linked news
Bull2
Bear2
Zymeworks Inc.
30.13
+1.14 · +3.93%
post 30.14 +0.03%
Expected move
Inputsspot 30.13exp Nov 20ATM strike 30ATM straddle 3.30IV 64%